INS and type 1 diabetes mellitus: Induced pluripotent stem cell (iPSC) technology has ushered in a new era of regenerative medicine for treating type 1 diabetes (T1D), providing a potentially unlimited source of insulin-producing cells for transplantation and aiming to restore insulin independence [1–4].